Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Non-invasive Magnetic Resonance Elastography.

Li J, Zormpas-Petridis K, Boult JK, Reeves EL, Heindl A, Vinci M, Lopes F, Cummings C, Springer CJ, Chesler L, Jones C, Bamber JC, Yuan Y, Sinkus R, Jamin Y, Robinson SP.

Cancer Res. 2019 Oct 11. pii: canres.1595.2019. doi: 10.1158/0008-5472.CAN-19-1595. [Epub ahead of print]

PMID:
31604713
2.

A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.

George SL, Izquierdo E, Campbell J, Koutroumanidou E, Proszek P, Jamal S, Hughes D, Yuan L, Marshall LV, Carceller F, Chisholm JC, Vaidya S, Mandeville H, Angelini P, Wasti A, Bexelius T, Thway K, Gatz SA, Clarke M, Al-Lazikani B, Barone G, Anderson J, Tweddle DA, Gonzalez D, Walker BA, Barton J, Depani S, Eze J, Ahmed SW, Moreno L, Pearson A, Shipley J, Jones C, Hargrave D, Jacques TS, Hubank M, Chesler L.

Eur J Cancer. 2019 Sep 11. pii: S0959-8049(19)30446-0. doi: 10.1016/j.ejca.2019.07.027. [Epub ahead of print]

3.

In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis.

Yogev O, Almeida GS, Barker KT, George SL, Kwok C, Campbell J, Zarowiecki M, Kleftogiannis D, Smith LM, Hallsworth A, Berry P, Möcklinghoff T, Webber HT, Danielson LS, Buttery B, Calton EA, da Costa BM, Poon E, Jamin Y, Lise S, Veal GJ, Sebire N, Robinson SP, Anderson J, Chesler L.

Cancer Res. 2019 Oct 15;79(20):5382-5393. doi: 10.1158/0008-5472.CAN-18-2759. Epub 2019 Aug 12.

PMID:
31405846
4.

Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):522-523. doi: 10.1038/s41571-019-0236-y. No abstract available.

PMID:
31150022
5.

MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment.

Zormpas-Petridis K, Jerome NP, Blackledge MD, Carceller F, Poon E, Clarke M, McErlean CM, Barone G, Koers A, Vaidya SJ, Marshall LV, Pearson ADJ, Moreno L, Anderson J, Sebire N, McHugh K, Koh DM, Yuan Y, Chesler L, Robinson SP, Jamin Y.

Cancer Res. 2019 Jun 1;79(11):2978-2991. doi: 10.1158/0008-5472.CAN-18-3412. Epub 2019 Mar 15.

PMID:
30877107
6.

Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.

Watts E, Heidenreich D, Tucker E, Raab M, Strebhardt K, Chesler L, Knapp S, Bellenie B, Hoelder S.

J Med Chem. 2019 Mar 14;62(5):2618-2637. doi: 10.1021/acs.jmedchem.8b01947. Epub 2019 Feb 21.

7.

Challenges to curing primary brain tumours.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):509-520. doi: 10.1038/s41571-019-0177-5. Review.

8.

SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.

Carreno G, Boult JKR, Apps JR, Gonzalez-Meljem JM, Haston S, Guiho R, Stache C, Danielson LS, Koers A, Smith LS, Virasami A, Panousopoulos L, Buchfelder M, Jacques TS, Chesler L, Robinson S, Martinez-Barbera JP.

Endocr Relat Cancer. 2019 Jan 1. pii: ERC-18-0538.R1. doi: 10.1530/ERC-18-0538. [Epub ahead of print]

9.

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F, Yogev O, Eden GL, Booth S, Brownhill S, Vardon A, McConville CM, Cheng PN, Norris MD, Etchevers HC, Murray J, Ziegler DS, Chesler L, Schmidt R, Burchill SA, Haber M, De Santo C, Mussai F.

Cancer Res. 2019 Feb 1;79(3):611-624. doi: 10.1158/0008-5472.CAN-18-2139. Epub 2018 Dec 13.

10.

Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus.

Gonzalez Malagon SG, Lopez Muñoz AM, Doro D, Bolger TG, Poon E, Tucker ER, Adel Al-Lami H, Krause M, Phiel CJ, Chesler L, Liu KJ.

Nat Commun. 2018 Mar 19;9(1):1126. doi: 10.1038/s41467-018-03512-5.

11.

Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition.

Ferrucci V, de Antonellis P, Pennino FP, Asadzadeh F, Virgilio A, Montanaro D, Galeone A, Boffa I, Pisano I, Scognamiglio I, Navas L, Diana D, Pedone E, Gargiulo S, Gramanzini M, Brunetti A, Danielson L, Carotenuto M, Liguori L, Verrico A, Quaglietta L, Errico ME, Del Monaco V, D'Argenio V, Tirone F, Mastronuzzi A, Donofrio V, Giangaspero F, Picard D, Remke M, Garzia L, Daniels C, Delattre O, Swartling FJ, Weiss WA, Salvatore F, Fattorusso R, Chesler L, Taylor MD, Cinalli G, Zollo M.

Brain. 2018 May 1;141(5):1300-1319. doi: 10.1093/brain/awy039.

PMID:
29490009
12.

Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.

Zeid R, Lawlor MA, Poon E, Reyes JM, Fulciniti M, Lopez MA, Scott TG, Nabet B, Erb MA, Winter GE, Jacobson Z, Polaski DR, Karlin KL, Hirsch RA, Munshi NP, Westbrook TF, Chesler L, Lin CY, Bradner JE.

Nat Genet. 2018 Apr;50(4):515-523. doi: 10.1038/s41588-018-0044-9. Epub 2018 Jan 29.

13.

Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours.

Izquierdo E, Yuan L, George S, Hubank M, Jones C, Proszek P, Shipley J, Gatz SA, Stinson C, Moore AS, Clifford SC, Hicks D, Lindsey JC, Hill RM, Jacques TS, Chalker J, Thway K, O'Connor S, Marshall L, Moreno L, Pearson A, Chesler L, Walker BA, De Castro DG.

Oncotarget. 2017 Dec 6;8(67):112036-112050. doi: 10.18632/oncotarget.23000. eCollection 2017 Dec 19.

14.

Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle.

Büchel G, Carstensen A, Mak KY, Roeschert I, Leen E, Sumara O, Hofstetter J, Herold S, Kalb J, Baluapuri A, Poon E, Kwok C, Chesler L, Maric HM, Rickman DS, Wolf E, Bayliss R, Walz S, Eilers M.

Cell Rep. 2017 Dec 19;21(12):3483-3497. doi: 10.1016/j.celrep.2017.11.090.

15.

Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform.

Almeida GS, Panek R, Hallsworth A, Webber H, Papaevangelou E, Boult JK, Jamin Y, Chesler L, Robinson SP.

Br J Cancer. 2017 Sep 5;117(6):791-800. doi: 10.1038/bjc.2017.251. Epub 2017 Aug 8.

16.

From class waivers to precision medicine in paediatric oncology.

Pearson ADJ, Pfister SM, Baruchel A, Bourquin JP, Casanova M, Chesler L, Doz F, Eggert A, Geoerger B, Jones DTW, Kearns PR, Molenaar JJ, Morland B, Schleiermacher G, Schulte JH, Vormoor J, Marshall LV, Zwaan CM, Vassal G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium.

Lancet Oncol. 2017 Jul;18(7):e394-e404. doi: 10.1016/S1470-2045(17)30442-4. Review.

PMID:
28677575
17.

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD.

Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Review.

PMID:
28604107
18.

Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma.

Boult JKR, Apps JR, Hölsken A, Hutchinson JC, Carreno G, Danielson LS, Smith LM, Bäuerle T, Buslei R, Buchfelder M, Virasami AK, Koers A, Arthurs OJ, Jacques TS, Chesler L, Martinez-Barbera JP, Robinson SP.

Brain Pathol. 2018 Jul;28(4):475-483. doi: 10.1111/bpa.12525. Epub 2017 May 17.

19.

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

Tucker ER, Tall JR, Danielson LS, Gowan S, Jamin Y, Robinson SP, Banerji U, Chesler L.

Mol Oncol. 2017 Aug;11(8):996-1006. doi: 10.1002/1878-0261.12069. Epub 2017 May 31.

20.

Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.

Richards MW, Burgess SG, Poon E, Carstensen A, Eilers M, Chesler L, Bayliss R.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13726-13731. Epub 2016 Nov 11.

21.

Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma.

Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, Witt O, Fischer M, Chesler L, Eilers M.

Cancer Cell. 2016 Aug 8;30(2):357-358. doi: 10.1016/j.ccell.2016.07.002. Epub 2016 Aug 8. No abstract available.

22.

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.

Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, Palmer RH, Hallberg B.

Dis Model Mech. 2016 Sep 1;9(9):941-52. doi: 10.1242/dmm.024448. Epub 2016 Jul 7.

23.

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.

Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, Jamin Y, Robinson SP, Pearson A, Maira M, Weiss WA, Workman P, Chesler L.

Oncotarget. 2016 Sep 6;7(36):57525-57544. doi: 10.18632/oncotarget.10544.

24.

Implementation of mechanism of action biology-driven early drug development for children with cancer.

Pearson AD, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner D, Capdeville R, Caron H, Carleer J, Chesler L, Geoerger B, Kearns P, Marshall LV, Pfister SM, Schleiermacher G, Skolnik J, Spadoni C, Sterba J, van den Berg H, Uttenreuther-Fischer M, Witt O, Norga K, Vassal G; Members of Working Group 1 of the Paediatric Platform of ACCELERATE.

Eur J Cancer. 2016 Jul;62:124-31. doi: 10.1016/j.ejca.2016.04.001. Epub 2016 May 31. Review.

PMID:
27258969
25.

p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.

Yogev O, Barker K, Sikka A, Almeida GS, Hallsworth A, Smith LM, Jamin Y, Ruddle R, Koers A, Webber HT, Raynaud FI, Popov S, Jones C, Petrie K, Robinson SP, Keun HC, Chesler L.

Cancer Res. 2016 May 15;76(10):3025-35. doi: 10.1158/0008-5472.CAN-15-1939. Epub 2016 Mar 29.

26.

Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.

Smith JR, Moreno L, Heaton SP, Chesler L, Pearson AD, Garrett MD.

Mol Oncol. 2016 Apr;10(4):538-52. doi: 10.1016/j.molonc.2015.11.005. Epub 2015 Nov 19.

27.

Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.

Dolman ME, Poon E, Ebus ME, den Hartog IJ, van Noesel CJ, Jamin Y, Hallsworth A, Robinson SP, Petrie K, Sparidans RW, Kok RJ, Versteeg R, Caron HN, Chesler L, Molenaar JJ.

Clin Cancer Res. 2015 Nov 15;21(22):5100-9. doi: 10.1158/1078-0432.CCR-15-0313. Epub 2015 Jul 22.

28.

Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.

Tucker ER, Danielson LS, Innocenti P, Chesler L.

Cancer Res. 2015 Jul 15;75(14):2770-4. doi: 10.1158/0008-5472.CAN-14-3817. Epub 2015 Jun 29. Review.

29.

Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.

Mussai F, Egan S, Hunter S, Webber H, Fisher J, Wheat R, McConville C, Sbirkov Y, Wheeler K, Bendle G, Petrie K, Anderson J, Chesler L, De Santo C.

Cancer Res. 2015 Aug 1;75(15):3043-53. doi: 10.1158/0008-5472.CAN-14-3443. Epub 2015 Jun 8.

30.

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.

Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC.

Front Oncol. 2015 May 12;5:111. doi: 10.3389/fonc.2015.00111. eCollection 2015.

31.

Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Cheung BB, Tan O, Koach J, Liu B, Shum MS, Carter DR, Sutton S, Po'uha ST, Chesler L, Haber M, Norris MD, Kavallaris M, Liu T, O'Neill GM, Marshall GM.

Mol Oncol. 2015 Aug;9(7):1484-500. doi: 10.1016/j.molonc.2015.04.005. Epub 2015 Apr 29.

32.

Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.

Ahmad Z, Jasnos L, Gil V, Howell L, Hallsworth A, Petrie K, Sawado T, Chesler L.

PLoS One. 2015 Mar 18;10(3):e0119834. doi: 10.1371/journal.pone.0119834. eCollection 2015.

33.

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.

Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, Boult JK, Williamson D, Ahmad Z, Hallsworth A, Ryan SL, Poon E, Robinson SP, Ruddle R, Raynaud FI, Howell L, Kwok C, Joshi A, Nicholson SL, Crosier S, Ellison DW, Wharton SB, Robson K, Michalski A, Hargrave D, Jacques TS, Pizer B, Bailey S, Swartling FJ, Weiss WA, Chesler L, Clifford SC.

Cancer Cell. 2015 Jan 12;27(1):72-84. doi: 10.1016/j.ccell.2014.11.002. Epub 2014 Dec 18.

34.

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.

Umapathy G, El Wakil A, Witek B, Chesler L, Danielson L, Deng X, Gray NS, Johansson M, Kvarnbrink S, Ruuth K, Schönherr C, Palmer RH, Hallberg B.

Sci Signal. 2014 Oct 28;7(349):ra102. doi: 10.1126/scisignal.2005470.

PMID:
25351247
35.

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.

Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE.

Oncotarget. 2014 Sep 30;5(18):8737-49.

36.

Paraneoplasia, cancer development and immunity: what are the connections?

Chesler L.

Nat Rev Cancer. 2014 Jul;14(7):447-8. doi: 10.1038/nrc3766.

PMID:
25093228
37.

Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma.

Jamin Y, Glass L, Hallsworth A, George R, Koh DM, Pearson AD, Chesler L, Robinson SP.

PLoS One. 2014 Mar 25;9(3):e92886. doi: 10.1371/journal.pone.0092886. eCollection 2014.

38.

MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance.

Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson AD, Van Maerken T.

Curr Drug Targets. 2014 Jan;15(1):114-23. Review.

PMID:
24387312
39.

Identification of a neuronal transcription factor network involved in medulloblastoma development.

Lastowska M, Al-Afghani H, Al-Balool HH, Sheth H, Mercer E, Coxhead JM, Redfern CP, Peters H, Burt AD, Santibanez-Koref M, Bacon CM, Chesler L, Rust AG, Adams DJ, Williamson D, Clifford SC, Jackson MS.

Acta Neuropathol Commun. 2013 Jul 11;1:35. doi: 10.1186/2051-5960-1-35.

40.

Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach.

Kim PY, Tan O, Diakiw SM, Carter D, Sekerye EO, Wasinger VC, Liu T, Kavallaris M, Norris MD, Haber M, Chesler L, Dolnikov A, Trahair TN, Cheung NK, Marshall GM, Cheung BB.

J Proteomics. 2014 Jan 16;96:1-12. doi: 10.1016/j.jprot.2013.10.032. Epub 2013 Nov 4.

41.

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.

Barone G, Anderson J, Pearson AD, Petrie K, Chesler L.

Clin Cancer Res. 2013 Nov 1;19(21):5814-21. doi: 10.1158/1078-0432.CCR-13-0680. Epub 2013 Aug 21. Review.

42.

Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.

Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, Witt O, Fischer M, Chesler L, Eilers M.

Cancer Cell. 2013 Jul 8;24(1):75-89. doi: 10.1016/j.ccr.2013.05.005. Epub 2013 Jun 20. Erratum in: Cancer Cell. 2016 Aug 8;30(2):357-358.

43.

Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.

Jamin Y, Tucker ER, Poon E, Popov S, Vaughan L, Boult JK, Webber H, Hallsworth A, Baker LC, Jones C, Koh DM, Pearson AD, Chesler L, Robinson SP.

Radiology. 2013 Jan;266(1):130-40. doi: 10.1148/radiol.12120128. Epub 2012 Nov 20.

44.

CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.

Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, Hallsworth A, Smith EL, Boxall KJ, Lainchbury M, Matthews TP, Jamin Y, Robinson SP, Aherne GW, Reader JC, Chesler L, Raynaud FI, Eccles SA, Collins I, Garrett MD.

Clin Cancer Res. 2012 Oct 15;18(20):5650-61. doi: 10.1158/1078-0432.CCR-12-1322. Epub 2012 Aug 28.

45.

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE.

Cancer Cell. 2012 Jul 10;22(1):117-30. doi: 10.1016/j.ccr.2012.06.001.

46.

Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA.

Cancer Cell. 2012 May 15;21(5):601-13. doi: 10.1016/j.ccr.2012.04.012.

47.

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.

DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK.

Clin Cancer Res. 2012 May 1;18(9):2679-86. doi: 10.1158/1078-0432.CCR-11-3201. Epub 2012 Mar 15.

48.

miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.

Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, Chesler L, Stallings RL.

PLoS One. 2011;6(12):e28356. doi: 10.1371/journal.pone.0028356. Epub 2011 Dec 2.

49.

Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Chesler L, Weiss WA.

Semin Cancer Biol. 2011 Oct;21(4):245-55. doi: 10.1016/j.semcancer.2011.09.011. Epub 2011 Sep 21. Review.

50.

The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.

Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Jamin Y, Robinson SP, Workman P, Blagg J, Raynaud FI, Eccles SA, Chesler L, Linardopoulos S.

Mol Cancer Ther. 2011 Nov;10(11):2115-23. doi: 10.1158/1535-7163.MCT-11-0333. Epub 2011 Sep 1.

Supplemental Content

Loading ...
Support Center